Brief: Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH
10/12/2024 22:33
Dec 10 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM
CAHMELIA-204
IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH
* SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT
ACHIEVE
PRIMARY ENDPOINT
* SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC
OPPORTUNITIES AND
COST-REDUCTION ACTIVITIES
* SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND
CAHPTAIN-205 TRIALS
* SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S
INVESTMENT
IN TILDACERFONT FOR TREATMENT OF CAH
Source text: urn:newsml:reuters.com:*:nBw4yR7cQa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium